Skip to main content
. Author manuscript; available in PMC: 2018 Nov 1.
Published in final edited form as: Breast Cancer Res Treat. 2017 Jul 14;166(1):241–247. doi: 10.1007/s10549-017-4362-x

Table 3.

Cardiac Events

Events Entire Cohort
(n=165)

Cardiac Event (total) 12 (7.2)
LVEF Decline* 10 (6.1)
  ≥ 10% and < LLN 7 (4.2)
  ≥ 16% and ≥ LLN 3 (1.8)
Symptomatic heart failure (NYHA class III/IV) 2 (1.2)
Cardiac Death 0 (0)

Trastuzumab Interruption
  Cardiac 7 (4.2)
  Non-cardiac 11 (6.7)

Data given as no. (%). NYHA, New York Heart Association.

*

LVEF decline without severe (NYHA class III/IV) heart failure